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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYMesenchymal stem cells (MSCs) are a potential source of chondrogenic cells for the treatment of cartilage disorders, but loss of chondro-
genic potential during in vitro expansion and the propensity of cartilage to undergo hypertrophic maturation impede their therapeutic
application. Herewe report that the signaling proteinWNT3A, in combinationwith FGF2, supports long-term expansion of humanbone
marrow-derived MSCs. The cells retained their chondrogenic potential and other phenotypic and functional properties of multipotent
MSCs,whichwere gradually lost in the absence ofWNT3A.Moreover, we discovered that endogenousWNTsignals are themain drivers of
the hypertrophic maturation that follows chondrogenic differentiation. Inhibition of WNT signals during differentiation prevented
calcification and maintained cartilage properties following implantation in a mouse model. By maintaining potency during expansion
and preventing hypertrophic maturation following differentiation, the modulation of WNT signaling removes two major obstacles that
impede the clinical application of MSCs in cartilage repair.INTRODUCTION
Cartilage is an avascular, alymphatic, and aneural tissue
(Mankin, 1982) that, consequently, has limited repair ca-
pacity. Therefore, cartilage damage requires clinical in-
tervention. In the last two decades, cell-based therapies
have emerged as promising treatment options. Autologous
chondrocyte implantation (ACI) was first applied in 1994
and is still used to treat cartilage defects in human patients
(Brittberg et al., 1994). In ACI, however, chondrocytes are
harvested from the patient, creating an additional cartilage
defect. Moreover, before use, the chondrocytes require
in vitro expansion, which causes the progressive loss of
cartilagematrix gene expression (Benya et al., 1978; Mayne
et al., 1976).
Mesenchymal stem cells (MSCs) from adult tissues, with
their ability to differentiate into several cell types, chondro-
cytes included, have been investigated as an alternative cell
source (Dennis et al., 1999; Pittenger et al., 1999; Prockop,
1997). Unfortunately, despite their easy isolation and
in vitro expansion, the loss of stem cell characteristics
and differentiation potential with expansion (Banfi et al.,
2000; Bonab et al., 2006; Chen et al., 2005; Li et al.,
2011) and the induction of hypertrophic maturation
following chondrogenic differentiation (Hellingman
et al., 2010; Pelttari et al., 2006; Scotti et al., 2010) limitStem Ctheir appeal. Expansion of MSCs is improved in the pres-
ence of fibroblast growth factor 2 (FGF2) (Bianchi et al.,
2003; Quarto et al., 2001; Solchaga et al., 2005; Tsutsumi
et al., 2001), but FGF2 does not prevent the gradual loss
of cell multipotency or the subsequent formation of hyper-
trophic cartilage (Farrell et al., 2009; Hellingman et al.,
2010; Pelttari et al., 2006). A major challenge therefore is
to identify the factors that support MSC expansion while
maintaining their chondrogenic capacity, and additionally
the factors that regulate hypertrophic maturation.
To identify such factors, we took inspiration from the
process of cartilage and bone formation during embryonic
development. In developing mouse limbs, skeletal tissues
are generated by a rapidly expanding population of multi-
potent mesenchymal cells, found at the tip of the embry-
onic limb bud (Rabinowitz and Vokes, 2012; Zeller et al.,
2009). The expansion of these multipotent cells is driven
by the combination of WNT and FGF signals, secreted by
the apical ectodermal ridge (ten Berge et al., 2008a). The
combination of WNTand FGF proteins synergistically sup-
ports the expansion of these cells in vitro while maintain-
ing their multilineage potential (Cooper et al., 2011; ten
Berge et al., 2008a). Furthermore, WNT signals also play
an important role during cell differentiation, where their
ability to modulate chondrogenesis and induce osteogene-
sis is well established both in vitro (Churchman et al., 2012;ell Reports j Vol. 4 j 459–472 j March 10, 2015 j ª2015 The Authors 459
Figure 1. WNT3A in Combination with FGF2 Enhances Expansion and Chondrogenic Potential of MSCs
(A) Schematic overview of the experimental protocol. P0, passage 0; P1, passage 1.
(B and C) Proliferation rate of MSCs after 10 days of expansion (B; n = 4 donors) or up to six passages (C; n = 1 donor) (each symbol
represents a passage) in the indicated media. Lines indicate the polynomial regression representatives of the number of WF-MSCs
(+WNT+FGF; solid) or F-MSCs (+FGF; dotted).
(D) Thionine staining (glycosaminoglycan; GAG) and collagen type II immunostaining of representative sections from cartilage pellets
formed with cells expanded in the indicated conditions (n = 3 donors with three pellets per donor) after 5 weeks of chondrogenic
induction. The scale bar represents 1 mm.
(E) Analysis of the thionine-positive areas of pellet cultures chondrogenically differentiated in the indicated conditions (n = 3 donors with
three pellets per donor).
(F) Analysis of the pellet size of differentially expanded MSCs (n = 3 donors with three pellets per donor).
Values represent means ± SEM of three donors. *p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.01 compared to the other conditions.Dong et al., 2007; Jullien et al., 2012) and in vivo (Day et al.,
2005; Quarto et al., 2010a, 2010b).
In this paper, we show that the combination of WNT3A
and FGF2 supports extensive expansion of adult human
bone marrow-derived MSCs over multiple passages while
maintaining robust chondrogenic potential. Further-
more, we show that inhibition of WNT signals during
chondrogenic differentiation prevents undesired hyper-
trophicmaturation, allowing the formation of stable carti-
lage in vivo.RESULTS
WNT3A and FGF2 Synergistically Promote MSC
Proliferation and Chondrogenic Potential
MSCs were isolated from adult human bone marrow aspi-
rates by selective plastic adherence (Figure 1A), followed
by phenotypic characterization using flow cytometry.460 Stem Cell Reports j Vol. 4 j 459–472 j March 10, 2015 j ª2015 The AuthThis confirmed the cells were positive (>95%) for the
MSC markers CD73, CD90, and CD105 and negative
(<0.5%) for the hematopoietic marker CD45 (Figure S1A).
Afterward, we verified that MSCs responded to WNT3A
protein by demonstrating the accumulation of nonphos-
phorylated b-CATENIN (Figure S1B) and induction of the
WNT target gene AXIN2 (Figure S1C). Treatment with
FGF2 did not influence nonphosphorylated b-CATENIN
accumulation (Figure S1B).
We next analyzed the effects ofWNT3A and FGF2 on cell
proliferation. We observed that treatment of MSCs with
either WNT3A or FGF2 enhanced cell proliferation to a
similar degree (Figure 1B). Moreover, proliferation was
further increased by combining WNT3A with FGF2,
showing a synergistic effect of the two factors (Figure 1B;
fold increase in cell number compared to +vehicle:
+WNT = 1.53; +FGF = 1.29; +WNT+FGF = 4.81). The syner-
gistic action of WNT3A and FGF2 maintained a constant
exponential expansion even after six passages, leading toors
Figure 2. WNT3A in Combination with
FGF2 Maintains Robust Chondrogenic
Potential of MSCs over Multiple Passages
(A) Schematic of the experimental plan.
(B) Cell-number analysis during MSC
expansion. Lines indicate the polynomial
regression representatives of the number of
WF-MSCs (+WNT+FGF; solid) or F-MSCs
(+FGF; dotted). Values represent means ±
SEM (n = 3 donors, three to four pellets per
donor).
(C and D) MSCs were expanded for up to four
passages in the indicated conditions, and
pellet cultures were initiated after each
passage (n = 3–5 MSC donors each passage,
three pellets per donor). Shown are repre-
sentative sections of the pellets after
5 weeks of chondrogenic induction, stained
for glycosaminoglycans (thionine staining).
Right: higher magnification of the inset
areas. Numbers of cells per mm2 are indi-
cated in the right panels (values represent
the mean ± SEM of measurements performed
in three different pellets from three MSC
donors). The scale bars represent 1 mm (left
panels) and 200 mm (right panels). Dbs, cell
doublings.an approximately 109-fold expansion, whereas in the pres-
ence of FGF alone expansion slowed down over time and
came practically to a halt after 30 days (Figure 1C).
Upon differentiation in pellet culture, although the
chondrogenic differentiation of MSCs was performed us-
ing the same chondrogenic medium composition, MSCs
expanded in the presence of both WNT3A and FGF2
(WF-MSCs) displayed an increased chondrogenic capacity
compared to cells expanded in the presence of FGF2 alone
(F-MSCs) (Figures 1D and 1E). Interestingly, WF-MSCs
formed larger pellets (Figure 1F) that contained higher
levels of the cartilage matrix components collagen type II
and glycosaminoglycans (Figures 1D and 1E). Nonetheless,
total cell numbers in the pellets were comparable through-
out the chondrogenic induction and between the condi-
tions, indicating that WF-MSCs produced more cartilageStem Cmatrix per cell upon differentiation compared to F-MSCs
(Figure S2). Cells expanded in the absence of FGF2, regard-
less of the presence of WNT3A, displayed a limited chon-
drogenic differentiation capacity (Figure 1D). Together,
these data indicate that WNT and FGF synergize to not
only increase proliferation but also enhance the chondro-
genic potential of MSCs after short-term expansion.
We next asked whether WF-MSCs could maintain their
chondrogenic potential when expanded over multiple pas-
sages. We passaged the cells every 5 days and assessed their
chondrogenic potential by pellet culture at every passage
(Figure 2A). Although WF-MSCs expanded faster (Fig-
ure 2B), they maintained robust chondrogenic potential
over the course of four passages (Figure 2C), whereas
F-MSCs gradually lost their ability to produce an extra-
cellular matrix rich in glycosaminoglycans (Figure 2D).ell Reports j Vol. 4 j 459–472 j March 10, 2015 j ª2015 The Authors 461
Figure 3. MSCs Expanded in the Presence
of WNT3A and FGF2 Display Accelerated
Chondrogenesis
(A and B) Relative gene expression levels of
COL2 and COL2B in pellet cultures from cells
expanded in the indicated conditions after 3
(A) or 5 (B) weeks of chondrogenic induc-
tion. Values represent means ± SEM (n = 3
donors with three pellets per donor). **p <
0.01, ***p < 0.001.
(C) Relative glycosaminoglycan content of
pellet cultures from cells expanded in the
indicated conditions. Lines indicate the
polynomial regression representatives of
the glycosaminoglycan accumulation in the
WF-MSCs (+WNT+FGF; solid) and F-MSCs
(+FGF; dotted).Cell-count analysis showed that pellets derived from WF-
MSCs contained more extracellular matrix and lower cell
density than pellets from F-MSCs (Figures 2C and 2D, right
panels). These observations demonstrate that both WNT
and FGF signals are required for the long-term expansion
of MSCs with high chondrogenic potential.
An additional benefit of the presence ofWNT3A andFGF2
during MSC expansion appeared when we observed the
faster differentiation of WF-MSCs compared to F-MSCs:
3 weeks after chondrogenic induction, expression levels of
collagen type II (COL2) and collagen type IIB (COL2B; a
splice variant of collagen type II expressed during late chon-
drogenesis; McAlinden et al., 2008) were twice as high in
WF-MSCs as in F-MSCs (Figure 3A). After 5 weeks, at the
end of the differentiation protocol, transcript levels were
not significantly different from each other (Figure 3B; +FGF
versus +WNT+FGF), indicating that the increased collagen
type II protein accumulation we observed (Figure 1D) was
the result of increased deposition earlier during differentia-
tion. In agreementwith this, we observed that glycosamino-
glycans accumulated faster in pellets formedwithWF-MSCs
than in F-MSC pellets (Figure 3C).
Although MSCs can express several WNT ligands (Cho
et al., 2006; Etheridge et al., 2004), endogenous WNT
signaling appears to play a negligible role in MSC expan-462 Stem Cell Reports j Vol. 4 j 459–472 j March 10, 2015 j ª2015 The Authsion, because we found no effects on cell proliferation or
subsequent differentiation when endogenous WNT pro-
teins were blocked by the WNT antagonist Fz8CRD or
when endogenous WNT production was inhibited by the
porcupine inhibitor IWP2 (Figure S3).
Together, these results demonstrate that WNT3A, in
cooperation with FGF2, not only enhances long-term
MSC chondrogenic potential but also accelerates their sub-
sequent chondrogenic differentiation.
In Vitro WNT Signaling Modulation Leads to Stable
Cartilage Formation In Vivo
A major obstacle preventing the use of MSCs for cartilage
repair is their tendency to initiate endochondral ossifi-
cation following chondrogenic differentiation. This can
be observed as accumulation of collagen type X (COL10),
matrix metalloproteinase 13 (MMP13; also known as colla-
genase 3), and alkaline phosphatase (ALP) during hypertro-
phic maturation (Hellingman et al., 2010, 2011), followed
by calcification of the tissue and blood vessel invasion,
steps that ultimately lead to bone formation (Farrell et al.,
2011; Scotti et al., 2010). Encouragingly, although WF-
MSCs demonstrated an enhanced chondrogenic poten-
tial, they did not display an increase in collagen type X
protein accumulation during chondrogenic differentiationors
(Figure 4A). Although COL10 expression was upregulated
after 3 weeks in pellet culture, in line with the faster
COL2 production, it did not further increase during the
last 2 weeks of differentiation (Figure 4B). In contrast,
F-MSCs continued to increase COL10, ultimately result-
ing in higher expression after 5 weeks of differentia-
tion (Figure 4B). Moreover, WF-MSCs also expressed lower
levels of MMP13 at both time points (Figure 4C). This
suggests thatWF-MSCsmay have a lower propensity to un-
dergo hypertrophic maturation during chondrogenic
induction.
We further investigated the stability of the cartilage by
implanting the differentiated pellets subcutaneously in
immunocompromised (NMRI nu/nu) mice for 8 weeks
(Figure 4D), a well-established model for testing cartilage
stability in vivo (De Bari et al., 2004; Pelttari et al., 2006).
We found that F-MSC-derived pellets displayed weak
collagen type II staining, large areas of calcification, and
blood vessel invasion (Figure 4E, left panels), indicating
the onset of endochondral ossification. In contrast, WF-
MSC-derived pellets were strongly positive for collagen
type II and displayed no blood vessel invasion after implan-
tation (Figure 4E, right panels). However, calcified cartilage
was observed, indicating that WF-MSCs ultimately under-
went endochondral ossification in vivo, although the pro-
cess may be delayed (Figure 4E).
Multiple reports indicate thatWNTsignals promote oste-
ogenic differentiation of multipotent progenitors during
endochondral ossification (Cawthorn et al., 2012; Day
and Yang, 2008). Indeed, the WNT target AXIN2 was ex-
pressed in MSCs during chondrogenic differentiation and
repressed by IWP2, indicating it was due to endogenous
WNT signals (Figure 4F). We therefore tested whether inhi-
bition of WNT signals during chondrogenic induction
would prevent hypertrophic maturation. When chondro-
genic differentiation was performed in the presence of
IWP2, both F-MSCs and WF-MSCs showed reduced
AXIN2 expression (Figure 4F). Although only small
changes inCOL10 andMMP13mRNA levels were observed,
ALP was strongly downregulated by IWP2 (Figure 4F).
Interestingly,WF-MSC-derived pellets displayed the lowest
levels of AXIN2, COL10, MMP13, and ALP and the highest
levels of glycosaminoglycan deposition and COL2, result-
ing in the greater COL2:COL10 ratio, particularly in the
presence of IWP2 (Figures 4F and 4G, upper panels; Fig-
ure S4). Importantly, upon implantation in NMRI nu/nu
mice, the IWP2-treated pellets derived from WF-MSCs dis-
played strong collagen type II staining, with no signs of
calcification or blood vessel invasion (Figure 4G). Alto-
gether, these results show that inhibition of endogenous
WNT production interferes with hypertrophic maturation
and supports the formation of cartilage from WF-MSCs
that remains stable in our in vivo model.Stem CWNT3A and FGF2 Maintain MSC Phenotype, Gene
Expression, and Multipotency over Multiple Passages
Because MSCs from bone marrow constitute a heteroge-
neous population of cells (Muraglia et al., 2000; Pittenger
et al., 1999), our findings suggest that, in the absence of
WNT signals, the chondrogenic progenitors are gradually
depleted during expansion. In order to evaluate this hypoth-
esis, we characterized the cells prior to chondrogenic differ-
entiation. Whereas WF-MSCs maintained a polygonal-like
phenotype during expansion, F-MSCs gradually acquired a
more heterogeneous and enlarged morphology (Figure 5A;
Figure S5A). We further characterized the phenotypic
composition of the expanding population using flow cy-
tometry for the MSC markers CD90, CD105, CD73,
CD166, CD271, and CD146 (Dominici et al., 2006; Her-
mida-Go´mez et al., 2011; Sacchetti et al., 2007). At passage 1,
>90%of the cells expressed theMSCmarkers CD90, CD105,
CD73, andCD166 regardless of the presence ofWNT3A (Fig-
ure 5B). Moreover, WF-MSCs displayed a higher expression
of CD271, a protein associated with the chondrogenic sub-
set of MSCs (Figure 5B) (Hermida-Go´mez et al., 2011).
CD146,which inbonemarrowmaybe amarker of osteopro-
genitor (Sacchetti et al., 2007), was lost from the cells inde-
pendent of treatment with WNT3A (Figure S5B).
Following expansion over four passages, F-MSCs had
decreased expression of CD90 and CD105, whereas this
expression wasmaintained in the presence ofWNT3A (Fig-
ure 5B). Furthermore, CD73 decreased in the absence of
WNT3A, whereas CD166 decreased in both conditions
but less in the presence of WNT3A (Figure 5B). Combined,
these data suggest that WNT3A in combination with FGF2
preferentially allowed the expansion of MSCs character-
ized by polygonal morphology, small cell size, and high
expression of CD90, CD105, CD73, CD166, and CD271.
Moreover, we investigated whether multipotency of the
cells was maintained (Figure 5C), and found that WNT3A
in combination with FGF2 retained the adipogenic and
osteogenic potential of the cells, even after four passages
(Figures 5D and 5E).
Finally, we investigated how WNT and FGF affect the
expression of genes involved in proliferation and cell-fate
commitment. MYC genes mediate the proliferative effect
of WNT in mouse chondrogenic progenitors (ten Berge
et al., 2008a). Interestingly, WNT3A and FGF together
maintained high levels of MYC and NMYC, although their
expression declined in the absence of WNT3A (Figure 5F).
The third MYC family member, MYCL1, was not detected
(data not shown). TWIST1 is associated with the uncom-
mitted and proliferative state of MSCs (Isenmann et al.,
2009) by stimulating ID1 and influencing cell differentia-
tion via the regulation of lineage-specific transcription fac-
tors (Menicanin et al., 2010; Yang et al., 2011). Again,
WNT3A together with FGF2 maintained high levels ofell Reports j Vol. 4 j 459–472 j March 10, 2015 j ª2015 The Authors 463
Figure 4. WNT Signaling Modulation In Vitro Prevents the Onset of Endochondral Ossification In Vivo
(A) Collagen type X immunostaining on pellet cultures obtained from WF-MSCs (+WNT+FGF) or F-MSCs (+FGF). Representative images of
three MSC donors. The scale bar represents 1 mm.
(legend continued on next page)
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TWIST1, ID1, and the chondrogenic master regulator
SOX9, whereas the levels of these markers declined with
the expansion in the absence of WNT3A (Figure 5F). In-
terestingly, TWIST1, ID1, and SOX9 were not responsive
to either WNT3A or FGF2 but only responded to simul-
taneous stimulation of these factors (Figure S5C), sug-
gesting a possible mechanism for their synergistic effect.
Combined, these data suggest that the combination of
WNT3A and FGF2 maintains the uncommitted and prolif-
erative state of MSCs by supporting the expression of
TWIST1 andMYC genes while maintaining their chondro-
genic potential by supporting SOX9 expression.DISCUSSION
MSCs from adult tissues are currently used in cartilage tis-
sue engineering but gradually lose their stem cell character-
istics during in vitro expansion, leading to a decreased
chondrogenic differentiation capacity (Banfi et al., 2000;
Bonab et al., 2006; Chen et al., 2005; Li et al., 2011). More-
over, the cartilage undergoes hypertrophic maturation
(Farrell et al., 2011; Hellingman et al., 2011). In this study,
we demonstrate that MSCs from adult human bone
marrow depend on WNT signals to maintain their chon-
drogenic potential during expansion. Furthermore, by
inhibitingWNT signaling during the subsequent chondro-
genic differentiation phase, we not only enhanced chon-
drogenesis further but also prevented the onset of endo-
chondral ossification in our in vivo model (Figure 6).
Several additional benefits arose from the use of WNT3A
protein during expansion of MSCs: the cells proliferated
faster, their subsequent chondrogenic differentiation took
less time, and expression of hypertrophic markers was
reduced. These findings have the potential to remove
several major obstacles to clinical application of MSCs in
the repair of large cartilage defects, reducing the time of cul-
turewhile increasing the quality of the engineered cartilage
and preventing calcification.(B and C) Gene expression analysis of the hypertrophic markers CO
chondrogenic induction. Pellets were obtained from MSCs (n = 3 donor
Values represent means ± SEM. *p < 0.05, **p < 0.01.
(D) Schematic overview of the in vivo experimental protocol.
(E) Pre and post in vivo analysis of pellets formed using F-MSCs (+FG
represents 1 mm. mCT: Quantum FX mCT 3D images of the calcified area
2 mm. H&E: hematoxylin and eosin staining on histological sections
vasion. The scale bar represents 1 mm. COL2: collagen type II immuno
(high magnification) and 400 mm (low magnification).
(F) Transcript analysis of pellet cultures formed with cells expanded
(/ST) or with IWP2 (/IWP2). Values represent means ± SEM of three
(G) Pre and post in vivo analysis of pellets formed using WF-MSCs ch
in vivo data are representative of samples from two MSC donors, four
Stem CThe positive effect of FGF2 on enhancing proliferation
and chondrogenic potential of MSCs is well established
(Handorf and Li, 2011; Mastrogiacomo et al., 2001;
Solchaga et al., 2005; Tsutsumi et al., 2001). Whereas
we find that FGF2 sustains cell proliferation for up to
20 cell doublings, some reports show that it sustains
cell proliferation up to 40–50 cell doublings (Auletta
et al., 2011; Banfi et al., 2000; Gharibi and Hughes, 2012;
Solchaga et al., 2010). However, in these studies, healthy
and young donors (an average of 30 years old) were used,
whereas we investigated cells from elderly patients, who
are more likely to require cartilage repair. In addition, these
studies report an average of 22 doublings in 40 days,
whereas we find that WNT3A and FGF2 support 30 cell
doublings in this time frame, despite the increased age of
the donors. Thus, WNT3A not only sustains prolonged
FGF2-promoted cell expansion but also enhances the pro-
liferation rate.
MSCs can express several WNT ligands (Cho et al., 2006;
Etheridge et al., 2004). This endogenous WNT signaling
may play a negligible role in MSC expansion, because we
found no significant effects on cell proliferation or subse-
quent differentiation when endogenous WNT proteins
were prevented. However, and in agreement with our find-
ings, it has been reported that inhibition of endogenous
WNT signaling specifically during MSC differentiation
increased their chondrogenic differentiation (Im et al.,
2011; Im and Quan, 2010). Furthermore, a decreased level
of b-CATENIN in differentiatingMSCs was previously asso-
ciatedwith the downregulation of the hypertrophicmarker
COL10 (Venkatesan et al., 2012), consistent with our
finding that WNT repression suppressed the induction of
hypertrophic markers.
We show that adult human MSCs expanded with
WNT3A and FGF2 retained some of their surface markers
after extensive expansion in vitro. WNT3A and FGF2 may
specifically support the expansion of a chondrogenic or
multipotent subset of MSCs, preventing the gradual accu-
mulation of cells that do not contribute to chondrogenesis.L10 (B) and MMP13 (C) on pellet cultures after 3 or 5 weeks of
s and three pellets per donor) expanded in the indicated conditions.
F) or WF-MSCs (+WNT+FGF). GAG: thionine staining. The scale bar
of two representative pellets per condition. The scale bar represents
of decalcified samples. Black arrowheads indicate blood vessel in-
histochemistry on pellet cultures. The scale bars represent 150 mm
in the indicated conditions and chondrogenically induced without
pellets from three MSC donors. *p < 0.05, **p < 0.01, ***p < 0.001.
ondrogenically differentiated with IWP2 (+WNT+FGF/IWP2). The
pellets per donor and condition. Scale bars are as defined in (E).
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Figure 5. WNT3A and FGF2 Maintain MSC Characteristics in Multiple Passages
(A) Cell morphology of MSCs expanded as indicated. The scale bar represents 200 mm.
(B) Flow cytometry analysis of WF-MSCs (+WNT+FGF) and F-MSCs (+FGF). The percentage represents the number of positive cells for the
indicated surface marker. Values are the mean of two MSC donors. NC, negative control.
(C) Schematic representation of the working plan for the multilineage differentiation.
(D) Von Kossa staining (calcium phosphate deposits) and ALPmRNA levels of MSCs expanded in the indicated conditions and subsequently
differentiated in osteogenic medium. The scale bar represents 150 mm.
(legend continued on next page)
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Figure 6. WNT Signaling Modulation Regulates Cell Fate of MSCs
WNT and FGF proteins maintain human MSCs in a multipotent and
proliferative state. Blocking WNT signaling during chondrogenic
differentiation prevents hypertrophic maturation of the cells.Evidence for this is the loss of SOX9 expression and the
accumulation of CD90-, CD105-, CD166-, and CD271-
negative populations in the absence of WNT3A. Selective
maintenance of a chondrogenic subpopulation may also
explain the accelerated chondrogenesis that WF-MSCs
undergo. CD146 was identified as a marker for bone
marrow-derived MSCs with osteoprogenitor capacity
in vivo (Sacchetti et al., 2007). Upon expansion with
FGF2, with or without WNT3A, we find no CD146 expres-
sion; however, the cells retain proliferation and multiline-
age differentiation potential, in particular in the presence
of WNT3A. Thus, although CD146 may be an in vivo
marker for MSCs, it does not mark multipotent MSCs after
in vitro expansion.
Genes associated with theWNT pathway have been indi-
cated as potential candidates to maintain MSCs in an
uncommitted state and to enhance their proliferation ca-
pacity (Boland et al., 2004; Cho et al., 2006). We have pre-
viously shown that WNT and FGF signals interact during
embryonic cartilage development to stimulate mesen-
chymal cell proliferation while maintaining their multipo-
tency (ten Berge et al., 2008a). In that system, WNT and
FGF synergize in promoting cell proliferation by inducing
NMYC, which mediates cell-cycle entry in response to
proliferative signals while simultaneously preventing
chondrogenic differentiation by repressing the essential
chondrogenic regulator SOX9 (ten Berge et al., 2008a).
This difference may arise from the different experimental(E) Oil red O staining (lipid accumulation) and FABP4 mRNA levels
differentiated in adipogenic medium. The scale bar represents 100 m
Transcript analysis in (D) and (E) was performed on P4 expanded ce
donors; P4 images are representative of three MSC donors. **p < 0.0
(F) Gene expression profile of MSCs expanded in the indicated conditio
are representative of three MSC donors with two biological replicates
Stem Ccontexts: whereas our human MSCs were in an undiffer-
entiated, expanding state, the mouse cells had started to
differentiate along the chondrogenic lineage, thereby
strongly upregulating SOX9.Whereas in themouse system,
WNT prevents the upregulation of SOX9, in expanding
human MSCs the maintenance of SOX9 may indicate the
preservation of chondrogenic potential. Consistent with
this, the induction of SOX9 goes in parallel with a synergis-
tic effect of WNT3A and FGF2 on TWIST1 expression, a
marker commonly associated with an uncommitted state
(Isenmann et al., 2009; Menicanin et al., 2010).
Our findings underline the importance of stage-depen-
dent modulation of WNT signals in leading MSCs toward
a stable cartilage fate, and also indicate how insights
obtained from developmental biology contribute to ge-
nerating new strategies for regenerative medicine. Prior to
clinical translation, more prolonged in vivo experiments
in larger animals may be needed to validate the benefit of
WNT signaling modulation. Moreover, alternative delivery
methods for the cells, for example cell suspensions in
injectable hydrogels, may increase the applicability for tis-
sue-engineering approaches.EXPERIMENTAL PROCEDURES
Purified WNT3A and WNT Inhibitors
WNT3A was purified from cell-culture medium conditioned by
Drosophila S2 cells modified with a mouse WNT3A expression
vector as described (Willert et al., 2003). The purified protein was
obtained as a solution of 50 mg ml1 in PBS + 1% 3-[(3-cholami-
dopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). The
competitor of the WNT receptor Frizzled, Fz8CRD, was produced
as a fusion protein (Fz8CRD-IgG) as previously described (Hsieh
et al., 1999). The WNT-secretion inhibitor N-(6-methyl-2-benzo-
thiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyr-
imidin-2-yl)thio]-acetamide (IWP2) was purchased from Stemgent
and dissolved in DMSO, obtaining a stock solution of 2mM. IWP2
specifically inhibits the maturation (endogenous production) of
WNT proteins by blocking the acyltransferase enzyme porcupine.
Cell Source and Isolation of MSCs from Bone Marrow
Adult human MSCs from bone marrow were obtained from
femoral biopsies of donors (age 50–78 years) undergoing total
hip replacement, after signed informed consent and with approval
of the local ethical committees (Erasmus MC number MEC-2004-
142; Albert Schweizer Hospital number 2011.07). Cells from
bone marrow aspirates were seeded at a density of approximatelyof MSCs expanded in the indicated conditions and subsequently
m.
lls. Images of P1 cells are representative of two independent MSC
1.
ns prior to differentiation. Values represent means ± SEM. The data
per donor. *p < 0.05, **p < 0.01.
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50,000 nucleated cells cm2 in alpha-MEM (GIBCO), supple-
mented with 10% fetal calf serum (FCS), 1 ng ml1 FGF2 (AbD
Serotec), 25 mg ml1 ascorbic acid-2-phosphate (Sigma-Aldrich),
1.5 mgml1 fungizone, and 50 mgml1 gentamicin. MSCs were iso-
lated by their ability to adhere to plastic culture flasks. After 24 hr,
nonadherent cells were washed out and adherent cells were
cultured in standard conditions (5% CO2 at 37
C) for 10 ± 2
(mean ± SD, n = 6 donors) days. Medium was renewed three times
per week.WhenMSCsneared confluence, theywere detachedwith
0.05% trypsin and characterized by flow cytometry. Cells were
resuspended at 750,000 cells ml1 in FACSFlow solution (BD
Biosciences).
Expansion Phase
After isolation, MSCs were trypsinized using 0.05% trypsin and re-
seeded at a density of 2,300 cells cm2 in alpha-MEM + 10% FCS +
25 mg ml1 ascorbic acid-2-phosphate supplemented as follows:
(1) no supplementation (+vehicle)
(2) + 250 ng ml1 WNT3A (+WNT)
(3) + 1 ng ml1 FGF2 (+FGF)
(4) + 250 ng ml1 WNT3A + 1 ng ml1 FGF2 (+WNT+FGF)
(5) + 250 ng ml1 WNT3A + 1 ng ml1 FGF2 + 2 mM IWP2
(+WNT+FGF+IW)
(6) + 1 ng ml1 FGF2 + 2 mM IWP2 (+FGF+IW)
(7) + 1 ng ml1 FGF2 + 2 mg ml1 Fz8CRD (+FGF+FZ).
The concentrations ofWNT3A and FGF2 usedwere based on pre-
vious reports (Martin et al., 1997; ten Berge et al., 2008b, 2011).
Vehicle consisted of PBS + 1% CHAPS and/or DMSO, as applicable.
Mediumwas renewed every 24 hr. After one passage (P1), cells were
harvested, counted, and used to assay the chondrogenic potential
by pellet culture. Alternatively, MSCs were expanded up to P4 us-
ing an expansion condition in the presence of FGF2 or WNT3A
and FGF2.With every passage in amonolayer, cells were harvested,
counted, and then transferred to a pellet-culture system to assess
the chondrogenic potential or replaced for the next expansion.
Cell doublings were determined using the following formula: dou-
blings = log2 (cells at the end of the passage/cells seeded).
FACS Analysis
Cells were resuspended at 750,000 cells ml1 in FACSFlow solution
(BD Biosciences) and stained with antibodies against human
CD45-PerCp (345809), CD73-PE (550257), CD140a-PE (556002),
CD146-FITC (560846), CD166-PE (559263), CD271-Alexa Fluor
(560326) (BD Biosciences), CD90-APC (FAB2067A), and CD105-
FITC (FAB10971F) (R&D Systems), following the manufacturer’s
guidelines. Unstained samples were used as negative controls.
Flow cytometry analysis was performed using the BD FACSCanto
II apparatus (BD Biosciences), and data were analyzed using BD
FACSDiva software (BD Biosciences).
Chondrogenic Differentiation
After expansion, MSCs were harvested and centrifuged at 200 3 g
for 8min to obtain pellets of 200,000 cells. Chondrogenic differen-
tiation was induced by culturing the cells for 5 weeks in chondro-
genic medium consisting of DMEM-high-glucose GlutaMAX+
(GIBCO), 1:100 insulin, transferrin, and selenous acid (ITS+; BD
Biosciences), 40 mg ml1 L-proline (Sigma-Aldrich), 1 mM sodium468 Stem Cell Reports j Vol. 4 j 459–472 j March 10, 2015 j ª2015 The Authpyruvate (GIBCO), 100 nM dexamethasone (Sigma-Aldrich),
10 ngml1 transforming growth factor b1 (TGF-b1; R&D Systems),
1.5 mg ml1 fungizone, and 50 mg ml1 gentamicin. Medium was
renewed twice a week. Alternatively, the WNT inhibitor IWP2
(2 mM) was added during the last 3 weeks of chondrogenic induc-
tion. For this experiment, medium was renewed three times per
week.
Gene Expression Analysis
Cells in monolayers were washed with PBS and treated on ice with
RLT lysis buffer (QIAGEN). After 3, 4, or 5 weeks in chondrogenic
induction medium, pellets were manually homogenized in RNA-
Bee (Tel-Test) and RNA was extracted by addition of 20% chloro-
form. In all cases, RNA was purified using an RNeasy Micro kit
(QIAGEN) and 1 mg of total RNA was reverse transcribed into
cDNA using a RevertAid First Strand cDNA synthesis kit (MBI Fer-
mentas). Polymerase chain reactions were performedwith TaqMan
Universal PCR MasterMix (Applied Biosystems) or SYBR Green
MasterMix (Fermentas) using an ABI PRISM 7000 apparatus.
Primers and probe sets (Table S1) were designed using Primer Ex-
press 2.0 software (Applied Biosystems). Data were normalized to
GAPDH after its identification as the more stable within the condi-
tions and over time. Relative expression was calculated according
to the 2DDCt formula (Schmittgen and Livak, 2008).
Cartilage Stability In Vivo
Pellets from P2-expanded cells were implanted subcutaneously in
10- to 14-week-old female NMRI nu/nu mice (Charles River Labo-
ratories). Themicewere anesthetized using amixture of isoflurane/
O2 and four pellets per donor and condition were implanted by a
blinded technician in two separate subcutaneous pockets. After
8 weeks, the animals were sacrificed and the samples were har-
vested, fixed in 4% formalin, and subjected to a microcomputed
tomography (mCT) scan. Afterward, samples were decalcified
with 10% EDTA in PBS (pH 7.4) for 5 days and then paraffin
embedded, sectioned, and used for (immuno)histochemistry. Ani-
mal experiments were carried out in the central animal facilities at
ErasmusMCwith approval of the Animal Experiments Committee
according to the national animals act (EMC 2429).
(Immuno)Histochemistry
In Vitro Samples
Pellets were fixed in 4% formalin and paraffin embedded. Four
sections (6 mm) of each samplewere stainedwith 0.4% thionine so-
lution (Sigma-Aldrich) in demineralized water to detect glycosami-
noglycans or immunostained to detect collagen type II or collagen
type X as previously described (Hellingman et al., 2010). Briefly,
antigen retrieval was performed with 0.1% pronase (Sigma-Al-
drich) in PBS for collagen type II and with 0.1% pepsin (Sigma-Al-
drich) in 0.5 M acetic acid (pH 2.0) for collagen type X staining.
Both stainings continued with incubation with 10 mg ml1 hyal-
uronidase (Sigma-Aldrich) in PBS. Then, sections were incubated
for 2 hr with primary antibody for collagen type II (II-II/II6B3;
Developmental Studies Hybridoma Bank, University of Iowa) or
16 hr with collagen type X (2031501005; Quartett). Alkaline phos-
phatase-labeled secondary antibodywas used in combinationwith
Neu Fuchsine substrate, resulting in a red staining. An isotype IgG1ors
monoclonal antibody was used as a negative control. NIH ImageJ
freeware was used to evaluate the size of the pellets on sections
taken from the middle of the pellet and the percentage of the thi-
onine-positive areas and to quantify the number of cells per mm2
in the sections stained by thionine.
In Vivo Samples
After 8 weeks in vivo, pellets were decalcified as described above,
paraffin embedded, sectioned, and either immunostained for
collagen type II or stained with hematoxylin (Sigma-Aldrich) for
5min followed by counterstaining with 2% eosin solution (Merck)
in 50% ethanol. Collagen type II immunostaining was performed
as described for the in vitro samples but using the primary anti-
body previously incubated overnight with a goat anti-mouse
biotin-conjugated antibody (115-066-062; Jackson ImmunoRe-
search Europe). An isotype IgG1 monoclonal antibody was used
as a negative control. All the (immuno)histological evaluations
were performed in collaboration with an experimentally blinded
technician.
DNA and Glycosaminoglycan Quantification
Pellets at days 3, 7, 10, 14, 17, 21, 24, 28, 31, and 35 of culture were
digestedwith 300 ml of proteinase K solution (1mgml1 proteinase
K, 50 mM Trizma base, 1 mM EDTA, 1 mM iodoacetamide,
10 mg ml1 pepstatin [pH 7.6]; all from Sigma-Aldrich) for 16 hr
at 60C. After digestion, proteinase K was inactivated for 10 min
at 105C.
DNA Quantification
Five to 20 ml of each proteinase K-digested sample was loaded in
technical triplicate on an ice-cold 96-well plate. After incubation
with heparin (8.3 U ml1 in PBS; Leo Pharma) and RNase solution
(0.05 mg ml1 in PBS; Sigma-Aldrich), 50 ml of ethidium bromide
(25 mg ml1 in PBS; GIBCO) was added to each sample. Using the
Wallac 1420 VICTOR2 (PerkinElmer) apparatus, the ratio between
the absorbance at 340 nm (extinction filter) and the absorbance at
590 nm (emission filter), corrected by the background (wells
loaded with PBS only), was calculated. Purified calf thymus DNA
(Sigma-Aldrich) was used to set the standard curve.
Glycosaminoglycan Assay
1,9-dimethylmethylene blue (DMB; Sigma-Aldrich) solution
(46 mM DMB, 40 mM glycine, 40 mM NaCl [pH 3.0]) was added
to proteinase K-digested samples (200 ml) and the 530:590 nm
absorbance ratio was measured to determine the glycosamino-
glycan amount, using chondroitin sulfate C (Sigma-Aldrich) as a
standard.
MicroCT Analysis
After in vivo implantation, pellets from twoMSC donors (n = 2 do-
nors, four pellets per donor and condition) were analyzed by the
Quantum FX mCT scanner (PerkinElmer) using the following set-
tings: isotropic voxel size of 10 mm, 70 kV, 160 mA, 5 mm field of
view, 3 min scan (FINE setting) per sample. Raw mCT images were
converted into 3D reconstructions using Quantum FX mCT soft-
ware (PerkinElmer).
Statistical Analysis
Datawere analyzedwith PASWStatistics 20 (SPSS). The normal dis-
tribution of data was confirmed using the Kolmogorov-SmirnovStem Ctest. An unpaired t test or a generalized mixed model was applied;
the different conditions were considered a fixed parameter and the
donors as a random factor. In the case of multiple comparisons,
Bonferroni post hoc test was performed. The extra sum of square
F test was used to compare the polynomial regressions shown in
Figures 2C and 3B. A Levene’s test verified the equality of variances
in the samples (homogeneity of variances). p < 0.05was considered
statistically significant.
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